Cybin Inc. officially adopted Helus Pharma as its primary commercial operating name, accompanied by legal corporate name changes for its various operating subsidiaries and the transition of its public market trading identity. This rebranding initiative reflects the company's strategic evolution from an early-stage research outfit into a mature, commercial-stage pharmaceutical enterprise focused on advancing advanced mental health treatments. Alongside this transition, the company updated its corporate branding, digital web presence, and ticker symbol alignment on major public stock exchanges to unify its global corporate identity under the Helus Pharma name.